Research Topics
| W W HopeSummaryAffiliation: University of Manchester Country: UK Publications
| Collaborators
|
Detail Information
Publications
Anidulafungin for neonatal hematogenous Candida meningoencephalitis: identification of candidate regimens for humans using a translational pharmacological approachPeter A Warn
The University of Manchester, Manchester Academic Health Science Centre, NIHR Translational Research Facility in Respiratory Medicine, University Hospital of South Manchester NHS Foundation Trust, Manchester, United Kingdom
Antimicrob Agents Chemother 56:708-14. 2012..Anidulafungin is effective for the treatment of experimental HCME. Higher dosages than those currently used for clinical care are required for maximal antifungal effect...- Population pharmacokinetics of voriconazole in adultsWilliam W Hope
The University of Manchester, Manchester Academic Health Science Centre, NIHR Translational Research Facility in Respiratory Medicine, University Hospital of South Manchester NHS Foundation Trust, Manchester, United Kingdom
Antimicrob Agents Chemother 56:526-31. 2012..v. dosing resulted in higher AUC(0-12) and trough concentrations compared with oral dosing. Sample collection times of 1, 2, 3, 4, 8, and 12 h after an i.v. infusion are maximally informative times for future pharmacokinetic studies... - The initial 96 hours of invasive pulmonary aspergillosis: histopathology, comparative kinetics of galactomannan and (1->3) ?-d-glucan and consequences of delayed antifungal therapyWilliam W Hope
The University of Manchester, Manchester Academic Health Science Centre, NIHR Translational Research Facility in Respiratory Medicine, University Hospital of South Manchester NHS Foundation Trust, Oxford Rd, Manchester, United Kingdom
Antimicrob Agents Chemother 54:4879-86. 2010..Galactomannan and (1?3)-?-d-glucan have similar kinetics and are comparable biomarkers of early invasive pulmonary aspergillosis. Antifungal treatment at ?48 h postinoculation is associated with suboptimal therapeutic outcomes... - Population pharmacokinetics of micafungin in neonates and young infantsWilliam W Hope
The University of Manchester, Manchester Academic Health Science Centre, NIHR Translational Research Facility in Respiratory Medicine, University Hospital of South Manchester NHS Foundation Trust, Manchester, UK
Antimicrob Agents Chemother 54:2633-7. 2010..A dosage of 10 mg/kg/day resulted in 82.6% of patients with areas under the concentration-time curve (AUCs) that are associated with near-maximal decline in fungal burden within the central nervous system (CNS)... - Antifungal pharmacokinetics and pharmacodynamics: bridging from the bench to bedsideW W Hope
The University of Manchester, Manchester Academic Health Science Centre, NIHR Translational Research Facility in Respiratory Medicine, University Hospital of South Manchester NHS Foundation Trust, Manchester, UK
Clin Microbiol Infect 15:602-12. 2009..Effective and safe regimens can thus be studied appropriately in clinical settings. This approach can, and should, be used to optimize antifungal therapy for a large number of clinical scenarios... - Invasion of the alveolar-capillary barrier by Aspergillus spp.: therapeutic and diagnostic implications for immunocompromised patients with invasive pulmonary aspergillosisWilliam W Hope
The University of Manchester, Manchester, UK
Med Mycol 47:S291-8. 2009..This review provides an overview of host defenses, the mechanisms by which the alveolar-capillary barrier is breeched by Aspergillus, and the implications for diagnosis and treatment of patients with invasive pulmonary aspergillosis... - Therapeutic drug monitoring for triazolesWilliam W Hope
School of Translational Medicine, The University of Manchester, Manchester, UK
Curr Opin Infect Dis 21:580-6. 2008..Therapeutic drug monitoring represents an important component for the routine use of the triazoles... - Optimization of the dosage of flucytosine in combination with amphotericin B for disseminated candidiasis: a pharmacodynamic rationale for reduced dosingWilliam W Hope
Department of Medicine, The University of Manchester, 1 800 Stopford Building, Oxford Road, Manchester, UK
Antimicrob Agents Chemother 51:3760-2. 2007..Here, we bridge the results of an experimental pharmacodynamic study to humans and demonstrate that a 5FC dosage of 25 mg/kg of body weight/day in four divided doses in combination with amphotericin B produces near-maximal effect... - Therapy for fungal diseases: opportunities and prioritiesDavid W Denning
School of Translational Medicine, Manchester Academic Health Science Centre, University of Manchester, University Hospital of South Manchester, Manchester M23 9LT, UK
Trends Microbiol 18:195-204. 2010..Earlier and more complete mycological diagnosis and improvements in underlying risk estimation will improve outcomes. The limitations of the current antifungal agents and opportunities for new developments are discussed... - Efficacy and safety of posaconazole for chronic pulmonary aspergillosisTimothy W Felton
Respiratory Research Group, Faculty of Medicine and the Human Sciences, The University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom
Clin Infect Dis 51:1383-91. 2010..We report the first use of posaconazole in patients with CPA... - Disseminated Candidiasis caused by Candida albicans with amino acid substitutions in Fks1 at position Ser645 cannot be successfully treated with micafunginJ L Slater
The University of Manchester, Manchester Academic Health Science Centre, NIHR Translational Research Facility in Respiratory Medicine, University Hospital of South Manchester NHS Foundation Trust, Manchester, United Kingdom
Antimicrob Agents Chemother 55:3075-83. 2011..Ser645 Fks1 Candida albicans mutants cannot be treated with either conventional or elevated dosages of micafungin and should be deemed resistant... - Surface response modeling to examine the combination of amphotericin B deoxycholate and 5-fluorocytosine for treatment of invasive candidiasisWilliam W Hope
Department of Medicine, University of Manchester, Manchester, UK
J Infect Dis 192:673-80. 2005..Our methods provide a way in which some of the complex issues surrounding antifungal combination treatment can be addressed... - Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effectPeter A Warn
School of Translational Medicine, 1 800 Stopford Building, University of Manchester, Oxford Road, Manchester M13 9PT, United Kingdom
Antimicrob Agents Chemother 53:3453-61. 2009..This study provides the experimental foundation for the use of isavuconazole in patients with disseminated candidiasis... - Pharmacokinetics and pharmacodynamics of amphotericin B deoxycholate, liposomal amphotericin B, and amphotericin B lipid complex in an in vitro model of invasive pulmonary aspergillosisJodi M Lestner
The University of Manchester, Manchester Academic Health Science Centre, NIHR Translational Research Facility in Respiratory Medicine, University Hospital of South Manchester NHS Foundation Trust, 1 800 Stopford Building, Oxford Road, Manchester M13 9PT, United Kingdom
Antimicrob Agents Chemother 54:3432-41. 2010..Confocal microscopy suggested that liposomes interacted directly with hyphae and host cells. The PK-PD relationships of the three most widely used formulations of AmB differ markedly within an in vitro lung model of IPA... - Toxicodynamics of itraconazole: implications for therapeutic drug monitoringJodi M Lestner
The University of Manchester, Manchester Academic Health Science Centre, NIHR Translational Research Facility in Respiratory Medicine, University Hospital of South Manchester NHS Foundation Trust, Manchester, UK
Clin Infect Dis 49:928-30. 2009..1 mg/L of itraconazole (measured using a bioassay) was the concentration level at which the population of patients was separated into 2 groups, each with a high and a low probability of toxicity... - Laboratory diagnosis of invasive aspergillosisW W Hope
School of Medicine, University of Manchester and Wythenshawe Hospital, Manchester, UK
Lancet Infect Dis 5:609-22. 2005..This review considers the application, utility, and limitations of the currently available and investigational diagnostic modalities for invasive aspergillosis... - Pharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hostsSusan J Howard
School of Translational Medicine, The University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom
Antimicrob Agents Chemother 55:4880-7. 2011..Higher human dosages of all three echinocandins are required to induce fungicidal effects in neutropenic hosts... - Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosingWilliam W Hope
Pediatric Oncology Branch, NCI NIH, CRC Room 1 5750, Bethesda, MD 20892 1100, USA
Antimicrob Agents Chemother 51:3714-9. 2007.... - Derivation of an in vivo drug exposure breakpoint for flucytosine against Candida albicans and Impact of the MIC, growth rate, and resistance genotype on the antifungal effectWilliam W Hope
Pediatric Oncology Branch, NCI NIH, CRC Rm 1 5750, 10 Center Dr, MSC 1100, Bethesda MD 20892 1100, USA
Antimicrob Agents Chemother 50:3680-8. 2006..The in vivo growth rate was a critical additional determinant of the exposure-response relationship. There was a relationship between the 5FC resistance genotype and the exposure-response relationship... - Effect of neutropenia and treatment delay on the response to antifungal agents in experimental disseminated candidiasisWilliam W Hope
Pediatric Oncology Branch, NCI NIH, CRC Room 1 5750, 10 Center Dr, MSC 1100, Bethesda, MD 20892 1100, USA
Antimicrob Agents Chemother 51:285-95. 2007..Neutrophils and the timely initiation of antifungal agents are critical determinants in the treatment of experimental disseminated candidiasis... - Pathogenesis of Aspergillus fumigatus and the kinetics of galactomannan in an in vitro model of early invasive pulmonary aspergillosis: implications for antifungal therapyWilliam W Hope
Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
J Infect Dis 195:455-66. 2007..Little is known about the pathogenesis of invasive pulmonary aspergillosis and the relationship between the kinetics of diagnostic markers and the outcome of antifungal therapy... - The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonatesWilliam W Hope
Immunocompromised Host Section, Pediatric Oncology Branch, CRC, Rm 1 5750, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
J Infect Dis 197:163-71. 2008..The outcome after antifungal therapy is often suboptimal, with few therapeutic options. Limited clinical data suggest that echinocandins may have role to play in the treatment of HCME... - Characterization and comparison of galactomannan enzyme immunoassay and quantitative real-time PCR assay for detection of Aspergillus fumigatus in bronchoalveolar lavage fluid from experimental invasive pulmonary aspergillosisAndrea Francesconi
Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, Bldg. 10-CRC, Rm. 1-5740, Bethesda, MD 20892, USA
J Clin Microbiol 44:2475-80. 2006..04). Use of the GM EIA and qPCR assay in conjunction with culture-based diagnostic methods applied to BAL fluid could facilitate accurate diagnosis and more-timely initiation of specific therapy... - Optimal treatment of hepatic abscessWilliam W Hope
Department of Minimally Invasive and Gastrointestinal Surgery, Carolinas Medical Center, Charlotte, North Carolina 28203, USA
Am Surg 74:178-82. 2008..40). We propose a treatment algorithm with small abscesses being treated with antibiotics alone; large, uniloculated abscess with percutaneous drainage plus antibiotics; and large, multiloculated abscessed treated with surgical therapy... - The pharmacology and clinical use of caspofunginWilliam W Hope
National Institutes of Health, 10 Center Dr, Bethesda, MD, 20892, USA
Expert Opin Drug Metab Toxicol 3:263-74. 2007.... - Molecular mechanisms of primary resistance to flucytosine in Candida albicansWilliam W Hope
Immunocompromised Host Section POB, NCI, NIH CRC, Room 1 5700, 10 Center Dr, MSC 1100, Bethesda, MD 20892 1100, USA
Antimicrob Agents Chemother 48:4377-86. 2004..A single resistant isolate, lacking the above polymorphism in FUR1, has a homozygous polymorphism in FCA1 that results in a glycine-to-aspartate substitution at position 28 in cytosine deaminase...